{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:53:09Z","timestamp":1776840789061,"version":"3.51.2"},"reference-count":196,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The prognosis for late-stage digestive system tumors is poor, largely due to the development of chemotherapy resistance. Although immunotherapy, particularly immune checkpoint inhibitors, has transformed the treatment landscape for some patients, strategies to further enhance the efficacy of combination therapies are still lacking, and the underlying mechanisms remain incompletely understood. To systematically address these therapeutic challenges and explore potential solutions, this review delineates the key mechanisms driving chemoresistance in digestive system tumors. It encompasses both cell-intrinsic mechanisms\u2014such as enhanced drug efflux and DNA repair pathways\u2014and extrinsic factors mediated by the tumor microenvironment (TME), including immune cell infiltration and metabolic reprogramming. A special emphasis is placed on the dual immunomodulatory roles of chemotherapy-induced immunogenic cell death (ICD) and its remodeling impact on the immune landscape. Given the considerable heterogeneity across digestive system cancers\u2014including gastric, colorectal, and hepatic malignancies\u2014the review also synthesizes recent advances in innovative combination strategies. These include immunochemotherapy, oncolytic virus, targeting of cancer stem cells (CSCs), epigenetic modulation, and nanoparticle-based drug delivery systems. Ultimately, this work aims to offer a theoretical foundation and strategic directions to overcome clinical drug resistance and advance precision oncology in digestive system tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1800910","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:25Z","timestamp":1776837265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemoresistance in the era of immunotherapy: challenges and novel combinatorial strategies for digestive system tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Lu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]},{"name":"Kunming Medical University","place":["Kunming, China"]},{"name":"Key Laboratory of Cancer Research, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Yi","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan)","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","article-title":"The 2019 Who classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650481","article-title":"Biomarkers in immunotherapy-based precision treatments of digestive system tumors","volume":"11","author":"Zeng","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-Pd cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4251\/wjgo.v15.i4.596","article-title":"Role of tumor-associated macrophages in common digestive system Malignant tumors","volume":"15","author":"Shen","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tips.2023.11.006","article-title":"Biomarkers and targeted therapy for cancer stem cells","volume":"45","author":"Liu","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5767","article-title":"Decoding the role of cancer stem cells in digestive tract tumors: Mechanisms and therapeutic implications (review)","volume":"67","author":"Cao","year":"2025","journal-title":"Int J Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216352","article-title":"Fatty acids in cancer chemoresistance","volume":"572","author":"Qin","year":"2023","journal-title":"Cancer Lett"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1595176","article-title":"Bcaa metabolism in cancer progression and therapy resistance: The balance between fuel and cell signaling","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13507","article-title":"Role of m5c methylation in digestive system tumors (review)","volume":"31","author":"Zhang","year":"2025","journal-title":"Mol Med Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: From the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp Mol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbrc.2022.01.033","article-title":"Identification of Ercc8 as a novel cisplatin-resistant gene in esophageal cancer based on genome-scale Crispr\/Cas9 screening","volume":"593","author":"Sui","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-25-2255","article-title":"Mismatch repair as a dynamic and clinically actionable vulnerability in cancer","volume":"85","author":"Piumatti","year":"2025","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: Promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200245","article-title":"Gas-Sting: A classical DNA recognition pathways to tumor therapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf141","article-title":"The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer","volume":"30","author":"Jiang","year":"2025","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33306","article-title":"Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer","volume":"148","author":"Slootbeek","year":"2021","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"Dnmt and Hdac inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2023.07.008","article-title":"Epigenetics as a determinant of radiation response in cancer","volume":"383","author":"Arechaga-Ocampo","year":"2024","journal-title":"Int Rev Cell Mol Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via Dsrna including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant P53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","article-title":"Cancer immune evasion through Kras and Pd-L1 and potential therapeutic interventions","volume":"21","author":"Watterson","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced Gm-Csf production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac9935","article-title":"Myc regulates the antitumor immune response through Cd47 and Pd-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123015","article-title":"Cancer stem cell markers: Symphonic masters of chemoresistance and immune evasion","volume":"355","author":"Sarabia-S\u00e1nchez","year":"2024","journal-title":"Life Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.molimm.2014.12.017","article-title":"Tgf-\u03b2 and Egf induced Hla-I downregulation is associated with epithelial-mesenchymal transition (Emt) through upregulation of Snail in prostate cancer cells","volume":"65","author":"Chen","year":"2015","journal-title":"Mol Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1391973","article-title":"Blocking the Cd47-Sirp\u03b1 axis by delivery of anti-Cd47 antibody induces antitumor effects in glioma and glioma stem cells","volume":"7","author":"Li","year":"2018","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12093","article-title":"New insights into the role of Emt in tumor immune escape","volume":"11","author":"Terry","year":"2017","journal-title":"Mol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03510-z","article-title":"Resveratrol induces Pd-L1 expression through Snail-driven activation of Wnt pathway in lung cancer cells","volume":"147","author":"Yang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.803974","article-title":"Cancer stem cells and the tumor microenvironment in gastric cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10593-3","article-title":"Cancer stem cells and the tumor microenvironment in tumor drug resistance","volume":"19","author":"Gao","year":"2023","journal-title":"Stem Cell Rev Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153761","article-title":"Mesenchymal stem\/stromal cells may decrease success of cancer treatment by inducing resistance to chemotherapy in cancer cells","volume":"14","author":"Ramuta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-4459","article-title":"Tumor immune microenvironment during epithelial-mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.06.004","article-title":"Snail-overexpressing cancer cells promote M2-like polarization of tumor-associated macrophages by delivering Mir-21-abundant exosomes","volume":"20","author":"Hsieh","year":"2018","journal-title":"Neoplasia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The Bcl2 family: From apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899238","article-title":"Mitochondrial inner membrane permeabilisation enables Mtdna release during apoptosis","volume":"37","author":"Riley","year":"2018","journal-title":"EMBO J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101846","article-title":"Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer","volume":"40","author":"Hashemi","year":"2024","journal-title":"Transl Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103751","article-title":"Glycochenodeoxycholic acid induces stemness and chemoresistance via the Stat3 signaling pathway in hepatocellular carcinoma cells","volume":"12","author":"Shi","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166512","article-title":"Epigenetic regulation of autophagy in gastrointestinal cancers","volume":"1868","author":"Ghavami","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578418","article-title":"The double-edge sword of autophagy in cancer: From tumor suppression to pro-tumor activity","volume":"10","author":"Chavez-Dominguez","year":"2020","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading Mhc-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143524","article-title":"Expression of chemoresistance-associated Abc proteins in hepatobiliary, pancreatic and gastrointestinal cancers","volume":"14","author":"Marin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100905","article-title":"Abc transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist Update"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117780","article-title":"Dynamic P-glycoprotein expression in early and late memory states of human Cd8 + T cells and the protective role of Ruxolitinib","volume":"182","author":"Biwott","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"14217","DOI":"10.1038\/s41598-020-71181-w","article-title":"Multidrug transporter Mrp4\/Abcc4 as a key determinant of pancreatic cancer aggressiveness","volume":"10","author":"Sahores","year":"2020","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1432851","article-title":"The xenobiotic transporter Abcc4\/Mrp4 promotes epithelial mesenchymal transition in pancreatic cancer","volume":"15","author":"Gancedo","year":"2024","journal-title":"Front Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01462","article-title":"Ca Ix stabilizes intracellular pH to maintain metabolic reprogramming and proliferation in hypoxia","volume":"10","author":"Benej","year":"2020","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123802","article-title":"Characteristics of the tumor microenvironment that influence immune cell functions: Hypoxia, oxidative stress, metabolic alterations","volume":"12","author":"Augustin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1331355","article-title":"Tumour response to hypoxia: Understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours","volume":"14","author":"Bigos","year":"2024","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1063423","article-title":"Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12885-021-09151-2","article-title":"Restricting tumor lactic acid metabolism using dichloroacetate improves T cell functions","volume":"22","author":"Rostamian","year":"2022","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910268","article-title":"Harnessing metabolic reprogramming to improve cancer immunotherapy","volume":"22","author":"Yan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2092234","article-title":"Co-delivery of carbonic anhydrase Ix inhibitor and doxorubicin as a promising approach to address hypoxia-induced chemoresistance","volume":"29","author":"Amin","year":"2022","journal-title":"Drug Delivery"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.12.004","article-title":"The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.5c00763","article-title":"Dual-regulated biomimetic nanocomposites for promoted tumor photodynamic immunotherapy","volume":"17","author":"Liao","year":"2025","journal-title":"ACS Appl Mater Interfac"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c02740","article-title":"Reprogrammed Ido-induced immunosuppressive microenvironment synergizes with immunogenic magnetothermodynamics for improved cancer therapy","volume":"16","author":"Wang","year":"2024","journal-title":"ACS Appl Mater Interfac"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303570","article-title":"Lncrnas-circrnas as rising epigenetic binary superstars in regulating lipid metabolic reprogramming of cancers","volume":"11","author":"Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123022","article-title":"Targeting lipid metabolism via nanomedicine: A prospective strategy for cancer therapy","volume":"317","author":"Huang","year":"2025","journal-title":"Biomaterials"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121502","article-title":"Disruption of dual homeostasis by a metal-organic framework nanoreactor for ferroptosis-based immunotherapy of tumor","volume":"284","author":"Zhang","year":"2022","journal-title":"Biomaterials"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2022.03.022","article-title":"Ferroptosis at the intersection of lipid metabolism and cellular signaling","volume":"82","author":"Liang","year":"2022","journal-title":"Mol Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13070828","article-title":"Targeting metabolic-redox nexus to regulate drug resistance: From mechanism to tumor therapy","volume":"13","author":"Wang","year":"2024","journal-title":"Antioxid (Basel)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113474","article-title":"Ccl2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment","volume":"153","author":"Yang","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the Ccl2\/Ccr2 axis in cancer immunotherapy: One stone, three birds","volume":"12","author":"Fei","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.08.004","article-title":"Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine","volume":"381","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"key":"B71","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12935-022-02717-5","article-title":"Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via Cxcl5\/Pi3k\/Akt\/Mtor pathway in gastric cancer","volume":"22","author":"Su","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226443","article-title":"Function of reactive oxygen species in myeloid-derived suppressor cells","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2024.10.006","article-title":"Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies","author":"Zhang","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i9.3820","article-title":"Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer","volume":"16","author":"Xia","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.7150\/thno.103175","article-title":"Tbx3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8843146","article-title":"Pd-L1 expression level displays a positive correlation with immune response in pancreatic cancer","volume":"2020","author":"Zhao","year":"2020","journal-title":"Dis Markers"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107443","article-title":"Pd-1\/Pd-L1 enhanced cisplatin resistance in gastric cancer through Pi3k\/Akt mediated P-Gp expression","volume":"94","author":"Wu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072057","article-title":"The matrix reloaded-the role of the extracellular matrix in cancer","volume":"15","author":"Raskov","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123770","article-title":"Cellular heterogeneity of pancreatic stellate cells, mesenchymal stem cells, and cancer-associated fibroblasts in pancreatic cancer","volume":"12","author":"Sunami","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-022-00898-1","article-title":"Pancreatic cancer, stroma, and exosomes","volume":"79","author":"Closa","year":"2023","journal-title":"J Physiol Biochem"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012010","article-title":"Fak activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer","volume":"12","author":"Zaghdoudi","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1966","article-title":"Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment","volume":"6","author":"Gong","year":"2022","journal-title":"Hepatol Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010973","article-title":"Organ specificity and heterogeneity of cancer-associated fibroblasts in colorectal cancer","volume":"22","author":"Miyashita","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2024.04.226","article-title":"Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin\/\u03b2-catenin\/Gpx4 axis in colorectal cancer","volume":"220","author":"Li","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor Tigit protects tumors from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1038\/s41467-025-63451-w","article-title":"Structural basis of Fusobacterium nucleatum adhesin Fap2 interaction with receptors on cancer and immune cells","volume":"16","author":"Sch\u00f6pf","year":"2025","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (Keynote-177): Final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (Keynote-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The Escort-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (Jupiter-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (Orient-15): Multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"Bmj"},{"key":"B97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (Checkmate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for Her2-negative advanced gastric cancer (Keynote-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for Her2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 Keynote-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from Imbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (anti-Ctla-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (Union): early outcomes of a multicenter randomized phase iii trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of mhc-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","article-title":"Beta2-microglobulin(B2m) in cancer immunotherapies: biological function, resistance and remedy","volume":"517","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102534","article-title":"Cathepsin-D-mediated mhc class I degradation contributes to immune evasion in colorectal cancer","volume":"7","author":"Zhan","year":"2026","journal-title":"Cell Rep Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2016.12.003","article-title":"Nlrc5\/Cita: a key player in cancer immune surveillance","volume":"3","author":"Yoshihama","year":"2017","journal-title":"Trends Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.07.006","article-title":"Hla class I antigen processing machinery defects in antitumor immunity and immunotherapy","volume":"7","author":"Maggs","year":"2021","journal-title":"Trends Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2041","article-title":"Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated spp1+ macrophages and fibroblasts","volume":"29","author":"Sathe","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-1571","article-title":"Loss of optineurin drives cancer immune evasion via palmitoylation-dependent ifngr1 lysosomal sorting and degradation","volume":"11","author":"Du","year":"2021","journal-title":"Cancer Discov"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70089","article-title":"Targeting mettl3 as a checkpoint to enhance t cells for tumour immunotherapy","volume":"14","author":"Wu","year":"2024","journal-title":"Clin Transl Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2022.11.018","article-title":"N-glycosylation regulates intrinsic ifn-\u03b3 resistance in colorectal cancer: implications for immunotherapy","volume":"164","author":"Krug","year":"2023","journal-title":"Gastroenterology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.Crc-22-0295","article-title":"A prrx1 signature identifies tim-3 and vista as potential immune checkpoint targets in a subgroup of microsatellite stable colorectal cancer liver metastases","volume":"3","author":"Nygaard","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.688961","article-title":"Tigit induces (cd3+) t cell dysfunction in colorectal cancer by inhibiting glucose metabolism","volume":"12","author":"Shao","year":"2021","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41419-020-02968-y","article-title":"Checkpoint regulator b7x is epigenetically regulated by hdac3 and mediates resistance to hdac inhibitors by reprogramming the tumor immune environment in colorectal cancer","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis"},{"key":"B116","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13027-025-00676-w","article-title":"Targeting fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions","volume":"20","author":"Kowsarkhizi","year":"2025","journal-title":"Infect Agent Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54476","article-title":"Pectin supplement significantly enhanced the anti-pd-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4161\/onci.1.2.19026","article-title":"Trial watch: chemotherapy with immunogenic cell death inducers","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B121","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/imr.13269","article-title":"Immunogenic cell death (icd) enhancers-drugs that enhance the perception of icd by dendritic cells","volume":"321","author":"Liu","year":"2024","journal-title":"Immunol Rev"},{"key":"B122","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cgas\u2013sting pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11647","article-title":"Pd-l1 expression increased by ifn-\u03b3 via jak2-stat1 signaling and predicts a poor survival in colorectal cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol Lett"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.728018","article-title":"From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment","volume":"11","author":"Fabian","year":"2021","journal-title":"Front Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13263","article-title":"Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: from basic science to clinical application","volume":"321","author":"Ghiringhelli","year":"2024","journal-title":"Immunol Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.20","article-title":"Gut microbiota modulation of chemotherapy efficacy and toxicity","volume":"14","author":"Alexander","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","article-title":"Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy","volume":"164","author":"Chrysostomou","year":"2023","journal-title":"Gastroenterology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali","year":"2022","journal-title":"Adv Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1441935","article-title":"Antagonistic roles of cgas\/sting signaling in colorectal cancer chemotherapy","volume":"14","author":"Liang","year":"2024","journal-title":"Front Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010960","article-title":"Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy","volume":"13","author":"Kalinski","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820980116","article-title":"Tumor vessel normalization: a window to enhancing cancer immunotherapy","volume":"19","author":"Li","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411799","article-title":"Predicting outcomes of atezolizumab and bevacizumab treatment in patients with hepatocellular carcinoma","volume":"24","author":"Han","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with pd-1\/pd-l1 antibodies and vegf inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-22-1002","article-title":"Elevated methionine flux drives pyroptosis evasion in persister cancer cells","volume":"83","author":"El-Kenawi","year":"2023","journal-title":"Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13046-023-02689-y","article-title":"Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer","volume":"42","author":"Yang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-01969-w","article-title":"Rtp4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer","volume":"58","author":"Yamamoto","year":"2023","journal-title":"J Gastroenterol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010066","article-title":"Hdac inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B142","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cac2.12313","article-title":"Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials","volume":"42","author":"Xu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1230","article-title":"Foxo1 degradation via g9a-mediated methylation promotes cell proliferation in colon cancer","volume":"47","author":"Chae","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02176","article-title":"Reversible lysine specific demethylase 1 (lsd1) inhibitors: a promising wrench to impair lsd1","volume":"64","author":"Dai","year":"2021","journal-title":"J Med Chem"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3427","article-title":"The effect of two nucleoside antitumor drugs on the proliferation and dna methylation of human gastric cancer cells","volume":"10","author":"Chen","year":"2015","journal-title":"Oncol Lett"},{"key":"B146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.01.006","article-title":"Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2\u2019-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics","volume":"363","author":"Wu","year":"2015","journal-title":"Cancer Lett"},{"key":"B147","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"Cgas-sting, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105749","article-title":"Cellular resistance to an oncolytic virus is driven by chronic activation of innate immunity","volume":"26","author":"Larrieux","year":"2023","journal-title":"iScience"},{"key":"B149","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cytogfr.2020.07.007","article-title":"Tumour vasculature: friend or foe of oncolytic viruses","volume":"56","author":"Santry","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003254","article-title":"Vcn-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coviro.2016.07.007","article-title":"Oncolytic herpes simplex virus interactions with the host immune system","volume":"21","author":"Saha","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006561","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced\/metastatic epithelial cancer: A phase I clinical trial (Spice)","volume":"11","author":"Fakih","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B154","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of Obp-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur J Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J Virol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.10.5368-5381.2004","article-title":"Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors","volume":"78","author":"Shayakhmetov","year":"2004","journal-title":"J Virol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines2020163","article-title":"Tumor restrictions to oncolytic virus","volume":"2","author":"V\u00e4h\u00e4-Koskela","year":"2014","journal-title":"Biomedicines"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.08.010","article-title":"A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon","volume":"30","author":"Yi","year":"2023","journal-title":"Mol Ther Oncolyt"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08346-4","article-title":"Intestinal microbiota modulates the antitumor effect of oncolytic virus vaccines in colorectal cancer","volume":"69","author":"Chen","year":"2024","journal-title":"Dig Dis Sci"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00766-x","article-title":"Gut microbiota in colorectal cancer development and therapy","volume":"20","author":"Wong","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/v14050888","article-title":"Cytokine responses to adenovirus and adenovirus vectors","volume":"14","author":"Atasheva","year":"2022","journal-title":"Viruses"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4772","article-title":"A novel oncolytic virus induces a regional cytokine storm and safely eliminates Malignant ascites of colon cancer","volume":"11","author":"Dong","year":"2022","journal-title":"Cancer Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023","journal-title":"ESMO Open"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/v7112905","article-title":"Oncolytic replication of E1b-deleted adenoviruses","volume":"7","author":"Cheng","year":"2015","journal-title":"Viruses"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: Barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolyt"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10959","article-title":"Ibuprofen reduces cell proliferation through inhibiting Wnt\/\u03b2 catenin signaling pathway in gastric cancer stem cells","volume":"42","author":"Akrami","year":"2018","journal-title":"Cell Biol Int"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6183","article-title":"Phenethyl isothiocyanate inhibits colorectal cancer stem cells by suppressing Wnt\/\u03b2-catenin pathway","volume":"32","author":"Chen","year":"2018","journal-title":"Phytother Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32667","article-title":"Verteporfin targeting Yap1\/Taz-Tead transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells","volume":"146","author":"Giraud","year":"2020","journal-title":"Int J Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937476","article-title":"Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-Pd-1 inhibitor therapy","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2021.01.022","article-title":"Polymeric micelles targeted against Cd44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo","volume":"331","author":"Andrade","year":"2021","journal-title":"J Control Release"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1563198","article-title":"Transforming cancer treatment: Integrating patient-derived organoids and Crispr screening for precision medicine","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081606","article-title":"Nanomedicines for overcoming cancer drug resistance","volume":"14","author":"Hu","year":"2022","journal-title":"Pharmaceutics"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101782","article-title":"Nanomaterials in the diagnosis and treatment of gastrointestinal tumors: New clinical choices and treatment strategies","volume":"32","author":"Chen","year":"2025","journal-title":"Mater Today Bio"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104731","article-title":"Nanodrug delivery: Strategies to circumvent nanoparticle trafficking by Kupffer cells in the liver","volume":"86","author":"Ezhilarasan","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2024.2375400","article-title":"Understanding nanoparticle-liver interactions in nanomedicine","volume":"21","author":"He","year":"2024","journal-title":"Expert Opin Drug Delivery"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1039\/d3lc00660c","article-title":"Modelling and breaking down the biophysical barriers to drug delivery in pancreatic cancer","volume":"24","author":"Kpeglo","year":"2024","journal-title":"Lab Chip"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S548825","article-title":"Strategies for pancreatic cancer-responsive nanodrug platforms targeting tumor hypoxic environments","volume":"20","author":"Joo","year":"2025","journal-title":"Int J Nanomed"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2024.2350356","article-title":"Nanomedicine for colon-targeted drug delivery: Strategies focusing on inflammatory bowel disease and colon cancer","volume":"19","author":"Kumar","year":"2024","journal-title":"Nanomed (Lond)"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.213","article-title":"The challenge and opportunity of gut microbiota-targeted nanomedicine for colorectal cancer therapy","volume":"3","author":"Wei","year":"2024","journal-title":"Imeta"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c11775","article-title":"Multiple immunomodulatory strategies based on targeted regulation of proprotein convertase subtilisin\/Kexin type 9 and immune homeostasis against hepatocellular carcinoma","volume":"18","author":"Fang","year":"2024","journal-title":"ACS Nano"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c08860","article-title":"Penetration cascade of size switchable nanosystem in desmoplastic stroma for improved pancreatic cancer therapy","volume":"15","author":"Zhao","year":"2021","journal-title":"ACS Nano"},{"key":"B182","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.medj.2024.02.012","article-title":"Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer","volume":"5","author":"Li","year":"2024","journal-title":"Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1039\/d3md00725a","article-title":"Responsive Zif-90 nanocomposite material: Targeted delivery of 10-hydroxycamptothecine to enhance the therapeutic effect of colon cancer (Hct116) cells","volume":"15","author":"Guo","year":"2024","journal-title":"RSC Med Chem"},{"key":"B184","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1038\/s41467-023-40439-y","article-title":"Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy","volume":"14","author":"Lang","year":"2023","journal-title":"Nat Commun"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.05.002","article-title":"Orally available dextran-aspirin nanomedicine modulates gut inflammation and microbiota homeostasis for primary colorectal cancer therapy","volume":"370","author":"Ma","year":"2024","journal-title":"J Control Release"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III Keynote-590 study","volume":"10","author":"Metges","year":"2025","journal-title":"ESMO Open"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.medj.2024.05.008","article-title":"Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The Escort-1st trial","volume":"5","author":"He","year":"2024","journal-title":"Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102623","article-title":"Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: Results from the randomized phase 3 Orient-15 study","volume":"72","author":"Lu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03069-4","article-title":"First-line pembrolizumab plus chemotherapy for Her2-negative advanced gastric cancer: China subgroup analysis of the randomized phase 3 Keynote-859 study","volume":"42","author":"Qin","year":"2025","journal-title":"Adv Ther"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The Orient-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: Rationale-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"Bmj"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28463","article-title":"First-line sugemalimab plus chemotherapy for advanced gastric cancer: The Gemstone-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"Jama"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III Keynote-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (Ibi305) versus sorafenib in unresectable hepatocellular carcinoma (Orient-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01462","article-title":"Patient-reported outcomes from the phase III Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.017","article-title":"Outcomes in the Asian subgroup of the phase III randomised Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"82","author":"Lau","year":"2025","journal-title":"J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:29Z","timestamp":1776837269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":196,"alternative-id":["10.3389\/fimmu.2026.1800910"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1800910","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1800910"}}